Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia On The Move: New CFDA Directors, AZ China GM

This article was originally published in PharmAsia News

Executive Summary

The China FDA has appointed several key directors and UK drug maker AstraZeneca has quietly changed its China head to a locally grown executive. Personnel changes also take place in major domestic maker Hisun, the China State Administration for Industry and Commerce (SAIC), Acucela and AdvaMed.

You may also be interested in...



Low Sinopharm Protection In Elderly Casts New Doubt On Chinese COVID-19 Vaccines

A new study in over 400 people reignites fears about the apparent low efficacy of Chinese COVID-19 vaccines, especially among the elderly, and adding to the debate around the need for booster shots.

As US, China Intensify Cybersecurity Crackdown, Companies Urged To Be Conservative

The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.

Fosun-BioNTech mRNA Vaccine Nears China Green Light

There is talk about offering booster shots to people who have already been fully vaccinated against COVID-19 in China and it’s increasingly clear that the mRNA vaccine from BioNTech/Fosun nearing approval could be the answer. Meanwhile, some Asian countries are turning away from Chinese coronavirus vaccines. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC088351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel